1
|
Loprinzi CL, Lustberg MB, Hershman DL, Ruddy KJ. Chemotherapy-induced peripheral neuropathy: ice, compression, both, or neither? Ann Oncol 2020; 31:5-6. [PMID: 31912795 DOI: 10.1016/j.annonc.2019.10.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Accepted: 10/14/2019] [Indexed: 11/30/2022] Open
Affiliation(s)
- C L Loprinzi
- Division of Medical Oncology, Mayo Clinic, Rochester, USA.
| | - M B Lustberg
- Internal Medicine/Division of Hematology-Oncology, Ohio State University, Columbus, USA
| | - D L Hershman
- Department of Medicine, Columbia University; New York City, USA
| | - K J Ruddy
- Division of Medical Oncology, Mayo Clinic, Rochester, USA
| |
Collapse
|
2
|
Leon-Ferre RA, Le-Rademacher J, Terstriep S, Glaser R, Novotni P, Giuliano A, Copur MS, Jones C, Page S, Mitchell W, Birrell SN, Loprinzi CL. Abstract P4-16-01: A randomized, double-blind, placebo-controlled trial of testosterone (T) for aromatase inhibitor-induced arthralgias (AIA) in postmenopausal women: Alliance A221102. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-16-01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Aromatase inhibitors are a mainstay hormone receptor-positive breast cancer treatment. AIA occur in up to 50% of patients (pts), adversely affecting quality of life and treatment compliance. A small phase II clinical trial of oral testosterone unedeconate appeared to improve AIA over placebo (P), with no significant androgenic side effects. The current study was performed to confirm these findings.
Methods: This randomized P-controlled trial enrolled postmenopausal women on adjuvant anastrozole or letrozole and experiencing moderate-to-severe AIA (≥5 on 0-10 scale). Pts were initially randomized to receive a subcutaneous pellet containing T 120 mg + anastrozole 8 mg (T+AIpellet) or P at the end of the first week on study (after obtaining baseline hot flash data) and at 3 months (mo). Due to slow accrual, the protocol was amended to change the route of delivery to topical T or P applied to the skin once daily for 6 mo. Baseline and monthly questionnaires were administered, including: Modified Brief Pain Inventory for aromatase arthralgia (BPI-AIA), prolife of mood states (POMS), the menopause specific quality of life questionnaire (MENQOL), a hot flash diary, the hot flash related daily interference scale (HFRDIS) and a symptom experience questionnaire. The primary endpoint was intra-patient change in joint pain at 3 mo, compared using a two-sample t-test.
Results: 227 pts were accrued between 9/1/2013-11/29/2017. 55 pts were randomized prior to the protocol amendment and received T+AIpellet or P. Baseline characteristics were balanced between arms, with the exceptions of median weight, BMI, hemoglobin (all higher in T arm), and breast tenderness, dissatisfaction with personal life/depression, and skin changes (all higher in P arm). Compared to baseline, there were no significant differences between T and P in average pain or joint stiffness at 3 (p=0.483) or 6 mo (p=0.573). Average pain was significantly lower each month compared to baseline, irrespective of treatment arm. There were no significant differences in any other items evaluated by BPI-AIA, POMS, MENQOL, hot flash diary or HFRDIS. Similarly, there were no substantial differences in toxicity. A subset analysis of the 55 pts randomized to receive T+AIpellet or P identified significant reductions in average pain scores with T+AIpellet during the first month (p=0.038), but not thereafter. T+AIpellet pts had significantly more reduction in reported % of baseline hot flash frequency (p=0.034) and score (p=0.031), nausea (p=0.019), fatigue (p=0.042), mood swings (p=0.026), hand/feet swelling (p=0.009), stress urinary incontinence (p=0.039) and changes in appearance, texture or tone of their skin (p=0.0083), than pts on P.
Conclusions: Overall, T did not improve AIA or menopausal symptoms compared to P. While there was significant improvement in AIA over the study period, T did not facilitate this process. However, T+AIpellet was associated with improvement in short-term AIA and several menopausal symptoms compared to P, suggesting that subcutaneous T combined with anastrozole may be superior to transdermal T alone.
Support: UG1CA189823, U10CA180820, U10CA189809; ClinicalTrials.gov Identifier: NCT01573442
Citation Format: Leon-Ferre RA, Le-Rademacher J, Terstriep S, Glaser R, Novotni P, Giuliano A, Copur MS, Jones C, Page S, Mitchell W, Birrell SN, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of testosterone (T) for aromatase inhibitor-induced arthralgias (AIA) in postmenopausal women: Alliance A221102 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-16-01.
Collapse
Affiliation(s)
- RA Leon-Ferre
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - J Le-Rademacher
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - S Terstriep
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - R Glaser
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - P Novotni
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - A Giuliano
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - MS Copur
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - C Jones
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - S Page
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - W Mitchell
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - SN Birrell
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| | - CL Loprinzi
- Mayo Clinic, Rochester, MN; Sanford Broadway Medical Center, Fargo, ND; Wright State University, Dayton, OH; Cedars-Sinai Medical Center, Los Angeles, CA; Saint Francis Cancer Treatment Center, Grand Island, NE; Georgia Cancer Specialists PC, Macon, GA; Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, KS; Novant Health Presbyterian Medical Center, Charlotte, NC; Havah Therapeutics Pty Ltd, Toorak Gardens, South Australia, Australia
| |
Collapse
|
3
|
Ruddy KJ, Sangaralingham LR, Freedman RA, Jemal A, Mougalian SS, Keegan T, Loprinzi CL, Gross CP, Henk HJ, Shah N. Abstract PD6-07: Trends in the cost of care for breast cancer among women with commercial insurance. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd6-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer care imposes a significant financial burden to U.S. healthcare systems and has become a key focus in the health care debate. Therapies for breast cancer are expensive, and the economic burden of these therapies may be rising due to the rapid introduction of pricey new drugs and techniques. There are limited data on the health care costs of individuals with breast cancer after initial diagnosis and how these costs have changed over time.
Methods: We conducted a retrospective analysis of commercially insured adult women with newly diagnosed non-metastatic breast cancer (identified via previously published claims-based algorithms) using 2007-2016 data from a large US health plan available in OptumLabs® Data Warehouse. We included patients with continuous health plan coverage for at least 2 years after initial diagnosis 2007-2014 and assessed how total health care spending and out-of-pocket costs (paid amounts) changed over this time. Costs were adjusted to 2016 US dollars using the general Consumer Price Index. Inpatient, outpatient, and outpatient pharmacy costs were evaluated. A multivariable logistic regression model was used to examine predictors of above average cost (cost > mean for that year of diagnosis).
Results: A total of 12,446 newly diagnosed breast cancer patients were identified (mean age, 51.6 years). Forty percent had undergone mastectomy, 38% chemotherapy, and 63% radiation. After adjustment for inflation, total healthcare costs increased 29.7% from 2007 to 2014 (Table 1), with increases primarily observed during the first year after diagnosis. Out-of-pocket costs remained relatively stable, and accounted for 5.3% of the total spending. Approximately 80% of the total costs were related to care received in the outpatient setting. Factors independently associated with above average spending included treatment with mastectomy [OR 1.78 (95% CI 1.5-2.1)], reconstruction [OR 3.0 (95% CI 2.6-3.5)], radiation [OR 4.0 (95% CI 3.4-4.7)] and chemotherapy [OR 18.4 (95% CI 16.6-20.3].
Table 1.Average healthcare spending over time Mean cost during first year after diagnosisMean cost during second year after diagnosisYear of diagnosistotalout-of-pockettotalout-of-pocket2007$80,296.17$4,271.25$16,559.21$1,907.012008$84,126.70$4,445.78$16,785.43$2,205.982009$88,331.45$4,728.42$17,005.68$2,214.932010$91,502.58$5,067.78$17,243.91$2,126.192011$93,826.40$5,089.45$16,862.45$2,027.962012$96,690.06$5,449.91$17,814.09$2,179.262013$104,064.93$5,678.19$17,087.47$2,115.972014$104,169.74$5,620.51$16,714.12$1,590.67
Conclusions: Breast cancer care is increasingly expensive during the first year after diagnosis, and costs are greatest for the recipients of more aggressive treatments. Costs during the second year after diagnosis have remained relatively stable.
Citation Format: Ruddy KJ, Sangaralingham LR, Freedman RA, Jemal A, Mougalian SS, Keegan T, Loprinzi CL, Gross CP, Henk HJ, Shah N. Trends in the cost of care for breast cancer among women with commercial insurance [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD6-07.
Collapse
Affiliation(s)
- KJ Ruddy
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; American Cancer Society, Atlanta, GA; Yale University School of Medicine, New Haven, CT; UC Davis Health, Sacramento, CA; Yale Cancer Center and Yale School of Medicine, New Haven, CT; Optum Labs, Eden Prairie, MN
| | - LR Sangaralingham
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; American Cancer Society, Atlanta, GA; Yale University School of Medicine, New Haven, CT; UC Davis Health, Sacramento, CA; Yale Cancer Center and Yale School of Medicine, New Haven, CT; Optum Labs, Eden Prairie, MN
| | - RA Freedman
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; American Cancer Society, Atlanta, GA; Yale University School of Medicine, New Haven, CT; UC Davis Health, Sacramento, CA; Yale Cancer Center and Yale School of Medicine, New Haven, CT; Optum Labs, Eden Prairie, MN
| | - A Jemal
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; American Cancer Society, Atlanta, GA; Yale University School of Medicine, New Haven, CT; UC Davis Health, Sacramento, CA; Yale Cancer Center and Yale School of Medicine, New Haven, CT; Optum Labs, Eden Prairie, MN
| | - SS Mougalian
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; American Cancer Society, Atlanta, GA; Yale University School of Medicine, New Haven, CT; UC Davis Health, Sacramento, CA; Yale Cancer Center and Yale School of Medicine, New Haven, CT; Optum Labs, Eden Prairie, MN
| | - T Keegan
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; American Cancer Society, Atlanta, GA; Yale University School of Medicine, New Haven, CT; UC Davis Health, Sacramento, CA; Yale Cancer Center and Yale School of Medicine, New Haven, CT; Optum Labs, Eden Prairie, MN
| | - CL Loprinzi
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; American Cancer Society, Atlanta, GA; Yale University School of Medicine, New Haven, CT; UC Davis Health, Sacramento, CA; Yale Cancer Center and Yale School of Medicine, New Haven, CT; Optum Labs, Eden Prairie, MN
| | - CP Gross
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; American Cancer Society, Atlanta, GA; Yale University School of Medicine, New Haven, CT; UC Davis Health, Sacramento, CA; Yale Cancer Center and Yale School of Medicine, New Haven, CT; Optum Labs, Eden Prairie, MN
| | - HJ Henk
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; American Cancer Society, Atlanta, GA; Yale University School of Medicine, New Haven, CT; UC Davis Health, Sacramento, CA; Yale Cancer Center and Yale School of Medicine, New Haven, CT; Optum Labs, Eden Prairie, MN
| | - N Shah
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; American Cancer Society, Atlanta, GA; Yale University School of Medicine, New Haven, CT; UC Davis Health, Sacramento, CA; Yale Cancer Center and Yale School of Medicine, New Haven, CT; Optum Labs, Eden Prairie, MN
| |
Collapse
|
4
|
Leon-Ferre RA, Novotny PJ, Faubion SS, Ruddy KJ, Flora D, Dakhil C, Rowland KM, Graham ML, Le-Lindqwister N, Loprinzi CL. Abstract GS6-02: A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study SC-1603. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs6-02] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HF occur in about 75% of midlife women and are associated with quality of life disruption and premature endocrine therapy discontinuation among breast cancer survivors. Estrogen therapy, effective for HF, is contraindicated in hormone receptor-positive breast cancer (BC). Previous studies have suggested that Oxy could be effective in managing HF.
Methods: This randomized, placebo (P)-controlled trial enrolled women who had experienced HF ≥28 times per week over >30 days and of sufficient severity to seek treatment. Patients (pts) were randomized to receive oral Oxy at two doses: 2.5mg BID for 6 weeks (Oxy2.5), 2.5mg BID for a week with subsequent increase to 5mg BID (Oxy5), or matching P, in equal ratios. Baseline and monthly questionnaires were administered including a HF diary, the HF related daily interference scale (HFRDIS) and a symptom experience questionnaire. The primary endpoint was intra-patient change in weekly HF score and frequency from baseline to end of study compared using Kruskal-Wallis tests.
Results: 150 pts were accrued between 2/23/2017-3/5/2018. 4 pts cancelled before starting treatment and were excluded from analyses. This interim report includes the first 104 pts for which at least one post-baseline evaluation was available. Baseline characteristics were well-balanced between the arms. Sixty-two percent were on tamoxifen or an aromatase inhibitor for the duration of the study. Pts on both Oxy doses had a significantly greater reduction in HF score and frequency compared to P. Pts on Oxy2.5 had a mean change in HF score of -10 (SD 7.4) vs -5.1 (SD 9.7) with P, p=0.003; and a mean change in average weekly number of HF of -4.6 (SD 3.1) vs -2.3 (SD 3.9), p=0.002. Pts on Oxy5 had a mean change in HF score of -16.2 (SD 5.1) vs -5.1 (SD 9.7) with P, p<0.001; and a mean change in average weekly number of HF of -7.0 (SD 4.0) vs -2.3 (SD 3.9), p<0.001. Repeated measures mixed models confirmed that, after adjusting for baseline values, both Oxy arms had significantly lower HF scores and frequency compared to P (p<0.001). HFRDIS revealed that pts in both Oxy arms experienced improvement in the following HF interference measures: work, social activities, leisure activities, sleep, relations, life enjoyment, and overall quality of life. Pts on Oxy5 also had improvement in HF interference with mood. Pts on Oxy2.5 experienced more stomach pain (p=0.031), diarrhea (p=0.007), nausea (p=0.04), headaches (0.032), episodes of confusion (0.012), dry mouth (p=0.003) and dry eyes (0.027) compared to P. Pts on Oxy5 experienced more constipation (0.004), dry mouth (0.001) and difficulty urinating (0.004) compared to P. There were no differences in study discontinuation due to adverse effects between either Oxy arm and P (Oxy2.5 vs P, p=0.653; Oxy5 vs P, p=0.483).
Conclusions: Oxy is superior to P for management of HF. Oxy2.5 and 5 were both associated with significant improvements in HF scores and frequency as well as improvement in HF interference with several quality of life measures. While pts on Oxy experienced more side effects than pts on P, rates of discontinuation due to adverse events were low.
This study was supported by the Breast Cancer Research Foundation.
Citation Format: Leon-Ferre RA, Novotny PJ, Faubion SS, Ruddy KJ, Flora D, Dakhil C, Rowland KM, Graham ML, Le-Lindqwister N, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study SC-1603 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS6-02.
Collapse
Affiliation(s)
- RA Leon-Ferre
- Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Camcer Cemter of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL
| | - PJ Novotny
- Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Camcer Cemter of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL
| | - SS Faubion
- Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Camcer Cemter of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL
| | - KJ Ruddy
- Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Camcer Cemter of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL
| | - D Flora
- Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Camcer Cemter of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL
| | - C Dakhil
- Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Camcer Cemter of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL
| | - KM Rowland
- Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Camcer Cemter of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL
| | - ML Graham
- Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Camcer Cemter of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL
| | - N Le-Lindqwister
- Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Camcer Cemter of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL
| | - CL Loprinzi
- Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Camcer Cemter of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL
| |
Collapse
|
5
|
Liu MC, Peng KW, Federspiel MJ, Russell SJ, Brunton BA, Zhou Y, Packiriswamy N, Hubbard JM, Loprinzi CL, Peethambaram PP, Ruddy KJ, Allred JB, Galanis E, Okuno SH. Abstract P6-21-03: Phase I trial of intratumoral (IT) administration of a NIS-expressing derivative manufactured from a genetically engineered strain of measles virus (MV). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-21-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The live attenuated non-pathogenic Edmonston MV vaccine strain has advantages as an oncolytic platform given its tumor specificity, potent bystander effect, and ability to be engineered and retargeted. MV-NIS expresses the human thyroidal sodium-iodide symporter (NIS) and is selectively oncolytic, entering tumor cells through CD46 (overexpressed on many cancers, including breast cancer of all subtypes) and Nectin-4. NIS expression in MV-NIS infected cells permits noninvasive monitoring of virus spread by SPECT-CT imaging of Tc-99m pertechnetate or I-123 uptake.
Methods: NCT01846091 is a standard 3+3 phase I trial of a single IT administration of MV-NIS in pts with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) or metastatic breast cancer (MBC). Primary objectives are (a) safety and tolerability and (b) maximally tolerated single dose. The secondary clinical objective is to preliminarily assess antitumor efficacy at and away from the MV injection site. Key eligibility criteria were: absence of standard therapy with life prolonging intent; at least one lesion >1 cm amenable to percutaneous injection; and no impending visceral crisis. MV-NIS was administered on D1 with mandatory SPECT-CT at baseline (BL) and on D3&D8; repeat SPECT-CT on D15&D21 if the prior result was positive; mandatory tumor biopsies on D3&D21; optional tumor biopsies on D8&D15; assessments for viremia and viral shedding at BL and on D3,D8,D15,D21; and standard imaging for restaging at BL,D21,W6,W12.
Results: Accrual completed with 12 evaluable pts (6 SCCHN and 6 MBC) at 3 dose levels (108, 3x108, 109 TCID50). The MBC group included 5 HR+/HER2- pts and 1 pt with mixed HR+/HER2- and HR+/HER2+ disease. 5 pts had evidence of disease progression prior to study participation. No dose limiting toxicities were observed among the MBC pts; AEs possibly related to MV-NIS in this group were gr2 fatigue, gr1 flu-like illness, gr2 lymphopenia (all n=1). No SCCHN responses were observed. Best response for the MBC pts was: stable disease (SD) >6 wks, n=4; clinical response, n=1; progression, n=1. One MBC pt with SD for 12 wks had positive SPECT/CT imaging at and away from the injection site on D3&D8 and was the only pt seronegative for measles IgG antibodies prior to MV-NIS exposure. The MBC pt who responded after initial MV-NIS exposure was the only pt with low viral RNA in blood (D3); she received additional doses at W9&W13 without toxicity through an expanded access protocol exemption and had disease progression by W19. No viral shedding was detected from mouth rinse or urine in any pt. MV was detected in tumor samples from all pts treated at the highest dose level. Additional blood and tissue analyses are in progress.
Conclusion: These results demonstrate the safety of IT MV-NIS administration, provide early evidence of biologic activity in MBC, and support the possibility of viral replication in tumors remote from the IT injection site. A MV strain encoding the immunomodulatory neutrophil activating protein transgene has been constructed (MV-s-NAP) with preclinical evidence of improved antitumor activity and immunogenicity. The phase I MV-s-NAP trial will start recruitment in Fall 2018.
Citation Format: Liu MC, Peng K-W, Federspiel MJ, Russell SJ, Brunton BA, Zhou Y, Packiriswamy N, Hubbard JM, Loprinzi CL, Peethambaram PP, Ruddy KJ, Allred JB, Galanis E, Okuno SH. Phase I trial of intratumoral (IT) administration of a NIS-expressing derivative manufactured from a genetically engineered strain of measles virus (MV) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-21-03.
Collapse
Affiliation(s)
- MC Liu
- Mayo Clinic, Rochester, MN
| | | | | | | | | | - Y Zhou
- Mayo Clinic, Rochester, MN
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
O'Sullivan CC, Van Houten HK, Sangaralingham L, Leal AD, Shinde S, Liu H, Ettinger D, Loprinzi CL, Ruddy KJ. Abstract P6-11-18: Ten year trends in antiemetic prescribing in cancer patients receiving highly emetogenic chemotherapy (HEC). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-11-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) is essential to preserve quality of life in cancer patients receiving highly emetogenic chemotherapy (HEC) such as doxorubicin-cyclophosphamide (AC) or cisplatin. Recently, new drugs (e.g. fosaprepitant and newer neurokinin 1 receptor antagonists [NK1RAs], rolapitant and netupitant) and updated guidelines for antiemetic use (e.g. adding olanzapine) have emerged. However, trends in real world antiemetic use are understudied.
Methods: We performed a retrospective study using the OptumLabs Data Warehouse (OLDW), which includes administrative claims for privately insured and Medicare Advantage enrollees in the U.S. We identified 34,236 patients age 18 years or older treated with either AC or cisplatin between January 2006 and June 2016. Data collected included baseline demographics (age, gender, census region and race), chemotherapy administered, and presence/absence of a central intravenous access device. Trends of anti-emetic use were presented overall and separately for 5-HT receptor antagonists (5HT3RAs) and NK1RAs.
Results: 23,030 patients (67.3%) received an anthracycline-based regimen (AC with or without docetaxel or paclitaxel), and 11,206 (32.7%) patients received cisplatin. Approximately two thirds of patients were female (n= 23,392). Dexamethasone use was stable over the decade (used by 85-90% in all years). Use of 5HT3RAs, primarily palonosetron and ondansetron, occurred in at least 95% of patients in all study years, consistent with guideline recommendations. NK1RAs were underutilized early on compared with guideline recommendations, but use increased to approximately 80% in the most recently evaluated year. Fosaprepitant use rose precipitously starting in 2009, preceding a sharp fall in aprepitant use beginning in 2011. The use of olanzapine, rolapitant and netupitant was minimal throughout the study period.
Conclusions: Dexamethasone and 5-HT3RAs were used in the vast majority of patients receiving HEC, in accordance with guideline recommendations. Less compliance with guidelines was seen with NK1RA use.
Citation Format: O'Sullivan CC, Van Houten HK, Sangaralingham L, Leal AD, Shinde S, Liu H, Ettinger D, Loprinzi CL, Ruddy KJ. Ten year trends in antiemetic prescribing in cancer patients receiving highly emetogenic chemotherapy (HEC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-11-18.
Collapse
Affiliation(s)
- CC O'Sullivan
- Mayo Clinic, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - HK Van Houten
- Mayo Clinic, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - L Sangaralingham
- Mayo Clinic, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - AD Leal
- Mayo Clinic, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - S Shinde
- Mayo Clinic, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - H Liu
- Mayo Clinic, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - D Ettinger
- Mayo Clinic, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - CL Loprinzi
- Mayo Clinic, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - KJ Ruddy
- Mayo Clinic, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| |
Collapse
|
7
|
Le-Rademacher J, Hillman SL, Meyers J, Loprinzi CL, Limburg PJ, Mandrekar SJ. Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials. Ann Oncol 2018; 28:1183-1190. [PMID: 28184420 DOI: 10.1093/annonc/mdx043] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Collection and reporting of adverse events (AEs) and their relatedness to study treatment, known commonly as attribution, in clinical trials is mandated by regulatory agencies (the National Cancer Institute and the Food and Drug Administration). Attribution is assigned by the treating physician using judgment based on various factors including patient's baseline status, disease history, and comorbidity as well as knowledge about the safety profile of the study treatments. We evaluate the patterns of AE attribution (unrelated, unlikely, possibly, probably, and definitely related to the treatment) in treatment, symptom intervention (cancer patients) and cancer prevention (participants at high risk for cancer) setting. Materials and methods Nine multicenter placebo-controlled trials (two treatment, two symptom intervention, and five cancer prevention) were analysed separately (2155 patients). Frequency and severity of AEs were summarized by arm. Attribution and percentage of repeated AEs whose attribution changed overtime were summarized for the placebo arms. Percentage of physician over- or under-reporting of AE relatedness was calculated for the treatment arms using the placebo arm as the reference. Results Across all trials and settings, a very high proportion of AEs reported as related to treatment were classified as possibly related, a significant proportion of AEs in the placebo arm were incorrectly reported as related to treatment, and clinician-reported attribution over-estimated the rate of AEs related to treatment. Fatigue, nausea, vomiting, diarrhea, constipation, and neurosensory were the common AEs that were over reported by clinician as related to treatment. Conclusions These analyses demonstrate that assigning causality to AE is a complex and difficult process that produces unreliable and subjective data. In randomized double-blind placebo-controlled trials where data are available to objectively assess relatedness of AE to treatment, attribution assignment should be eliminated.
Collapse
Affiliation(s)
| | | | - J Meyers
- Departments of Health Sciences Research
| | | | - P J Limburg
- Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA
| | | |
Collapse
|
8
|
Affiliation(s)
| | - N Majithia
- Department of Medicine, Mayo Clinic, Rochester, USA
| | - C L Loprinzi
- Department of Oncology; The Cancer Center. mailto:
| |
Collapse
|
9
|
Dueck AC, Singh J, Atherton P, Liu H, Novotny P, Hines S, Loprinzi CL, Perez EA, Tan A, Burger K, Zhao X, Diekmann B, Sloan JA. Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int 2015; 26:1971-7. [PMID: 25749740 PMCID: PMC4484303 DOI: 10.1007/s00198-015-3091-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Accepted: 02/25/2015] [Indexed: 10/23/2022]
Abstract
UNLABELLED Bone mineral density (BMD) measurement can vary depending upon anatomical site, machine, and normative values used. This analysis compared different BMD endpoints in two clinical trials. Trial results differed across endpoints. Future clinical trials should consider inclusion of multiple endpoints in sensitivity analysis to ensure sound overall study conclusions. INTRODUCTION Methodological issues hamper efficacy assessment of osteoporosis prevention agents in cancer survivors. Osteoporosis diagnosis can vary depending upon which bone mineral density (BMD) anatomical site and machine is used and which set of normative values are applied. This analysis compared different endpoints for osteoporosis treatment efficacy assessment in two clinical studies. METHODS Data from North Central Cancer Treatment Group phase III clinical trials N02C1 and N03CC (Alliance) were employed involving 774 patients each comparing two treatments for osteoporosis prevention. Endpoints for three anatomical sites included raw BMD score (RawBMD); raw machine-based, sample-standardized, and reference population-standardized T scores (RawT, TSamp, TRef); and standard normal percentile corresponding to the reference population-standardized T score (TPerc). For each, treatment arm comparison was carried out using three statistical tests using change and percentage change from baseline (CB, %CB) at 1 year. RESULTS Baseline correlations among endpoints ranged from 0.79 to 1.00. RawBMD and TPerc produced more statistically significant results (14 and 19 each out of 36 tests) compared to RawT (11/36), TSamp (8/36), and TRef (7/36). Spine produced the most statistically significant results (26/60) relative to femoral neck (20/60) and total hip (13/60). Lastly, CB resulted in 44 statistically significant results out of 90 tests, whereas %CB resulted in only 15 significant results. CONCLUSIONS Treatment comparisons and interpretations were different across endpoints and anatomical sites. Transforming via sample statistics provided similar results as transforming via reference or machine-based norms. However, RawBMD and TPerc may be more sensitive to change as clinical trial endpoints.
Collapse
Affiliation(s)
- A C Dueck
- Alliance Statistics and Data Center, Division of Health Sciences Research, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ, 85259, USA,
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Renfro LA, Grothey A, Kerr D, Haller DG, André T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ. Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†. Ann Oncol 2015; 26:950-958. [PMID: 25697217 DOI: 10.1093/annonc/mdv073] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Accepted: 02/05/2015] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Post-treatment survival experience of early colon cancer (CC) patients is well described in the literature, which states that cure is probable for some patients. However, comparisons of treated patients' survival versus that expected from a matched general population (MGP) are limited. PATIENTS AND METHODS A total of 32 745 patients from 25 randomized adjuvant trials conducted from 1977 to 2012 in 41 countries were pooled. Observed long-term survival of these patients was compared with expected survival matched on sex, age, country, and year, both overall and by stage (II and III), sex, treatment [surgery, 5-fluorouracil (5-FU), 5-FU + oxaliplatin], age (<70 and 70+), enrollment year (pre/post 2000), and recurrence (yes/no). Comparisons were made at randomization and repeated conditional on survival to 1, 2, 3, and 5 years. CC and MGP equivalence was tested, and observed Kaplan-Meier survival rates compared with expected MGP rates 3 years out from each landmark. Analyses were also repeated in patients without recurrence. RESULTS Within most cohorts, long-term survival of CC patients remained statistically worse than the MGP, though conditional survival generally improved over time. Among those surviving 5 years, stage II, oxaliplatin-treated, elderly, and recurrence-free patients achieved subsequent 3-year survival rates within 5% of the MGP, with recurrence-free patients achieving equivalence. CONCLUSIONS Conditional on survival to 5 years, long-term survival of most CC patients on clinical trials remains modestly poorer than an MGP, but achieves MGP levels in some subgroups. These findings emphasize the need for access to quality care and improved treatment and follow-up strategies.
Collapse
Affiliation(s)
- L A Renfro
- Division of Biomedical Statistics and Informatics.
| | - A Grothey
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - D Kerr
- Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - D G Haller
- School of Medicine, University of Pennsylvania, Philadelphia, USA
| | - T André
- Hôpital Saint Antoine, Paris; Pierre and Marie Curie University, Paris, France
| | - E Van Cutsem
- Digestive Oncology Unit, University Hospital Gasthuisberg/Leuven, Leuven, Belgium
| | - L Saltz
- Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - R Labianca
- Oncology Unit, Ospedale Giovanni XXIII, Bergamo, Italy
| | - C L Loprinzi
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - S R Alberts
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - H Schmoll
- Department for Internal Medicine IV, University Clinic Halle, Halle, Germany
| | - C Twelves
- Leeds Institute of Cancer and Pathology, University of Leeds and St James's University Hospital, Leeds Cancer Research UK Centre, Leeds, UK
| | - G Yothers
- National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Pittsburgh, USA
| | - D J Sargent
- Division of Biomedical Statistics and Informatics
| | | |
Collapse
|
11
|
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting side effect of many chemotherapeutic agents. Although many therapies have been investigated for the prevention and/or treatment of CIPN, there is no well-accepted proven therapy. In addition, there is no universally accepted, well-validated measure for the assessment of CIPN. The agents for which there are the strongest preliminary data regarding their potential efficacy in preventing CIPN are intravenous calcium and magnesium (Ca/Mg) infusions and glutathione. Agents with the strongest supporting evidence for efficacy in the treatment of CIPN include topical pain relievers, such as baclofen/amitriptyline/ketamine gel, and serotonin and norepinephrine reuptake inhibitors, such as venlafaxine and duloxetine. Other promising therapies are also reviewed in this paper. Cutaneous electrostimulation is a nonpharmacological therapy that appears, from an early pilot trial, to be potentially effective in the treatment of CIPN. Finally, there is a lack of evidence of effective treatments for the paclitaxel acute pain syndrome (P-APS), which appears to be caused by neurologic injury.
Collapse
Affiliation(s)
- D R Pachman
- Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | | | | | | |
Collapse
|
12
|
Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.cra9015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA9015 Background: Hot flashes are a common symptom during the menopause transition or following breast cancer treatment that can negatively impact the quality of life for many women. Preliminary data have suggested that flaxseed, a rich source of dietary lignans, may be a potentially effective treatment for hot flashes. Methods: A phase III randomized, placebo controlled trial was conducted to evaluate the efficacy of flaxseed in reducing hot flashes. Postmenopausal women were randomly assigned to a flaxseed bar (providing 410 mg of lignans) for 6 weeks vs a placebo bar. Participants completed daily prospective, self report hot flash diaries during the baseline week and then began eating one study bar per day for 6 weeks, while continuing to record their daily hot flashes. The intra-patient difference in hot flash activity between baseline and the last treatment week was the primary endpoint. Side effects of the bars were evaluated through self report and CTC assessment. Results: Between October and December 2009, 188 women were enrolled onto this trial. Mean hot flash scores were reduced by 4.9 units in the flaxseed group and 3.5 in the placebo group (p=0.29). In both groups, a little over a third of the women received a 50% reduction in their hot flash scores. Only one side effect was significantly different between groups, that being grade 1 pruritis, which was more common (7%) in the placebo group versus 1% in the flaxseed group. Both groups reported increased abdominal distension, flatulence, diarrhea and nausea. Adherence and ability to detect treatment assignment did not differ between groups. Conclusions: The results of this trial do not support the use of 410 mg of flaxseed lignans for the reduction of hot flashes. The gastrointestinal side effects seen in both groups were likely due to the fiber content in the flaxseed and placebo bars.
Collapse
Affiliation(s)
- S. Pruthi
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - R. Qin
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - S. A. Terstriep
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - H. Liu
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - T. R. C. Shah
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - K. F. Tucker
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - M. J. Bury
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - R. L. Carolla
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - P. D. Steen
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - J. Vuky
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - D. L. Barton
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| |
Collapse
|
13
|
Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.cra9015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Steensma DP, Sasu BJ, Sloan JA, Tomita D, Loprinzi CL. The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9031] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Reeves B, Dakhil SR, Sloan JA, Burger KN, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Lachance DH, Loprinzi CL. Paclitaxel-associated acute pain syndrome (P-APS) and its association on the development of peripheral neuropathy: NCCTG trial N08C1. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Loprinzi CL, Balcueva EP, Liu H, Kottschade LA, Stella PJ, Carlson MD, Moore DF, Zon R, Levitt R, Sloan JA. A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Barton DL, Moraska AR, Sood A, Sloan JA, Suh JJ, Griffin PC, Johnson DB, Ali AA, Silberstein PT, Loprinzi CL. Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Atherton PJ, Burger KN, Loprinzi CL, Miller RC, Jatoi A, Sloan JA. Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Wolf SL, Qin R, Menon SP, Rowland KM, Kugler JW, Flynn PJ, Christian D, Satele D, Berenberg JL, Loprinzi CL. Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Jones JM, Qin R, Bardia A, Linquist B, Wolf SL, Loprinzi CL. Prochlorperazine and 5HT3 antagonists for the treatment of breakthrough chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Pachman DR, Barton DL, Carns PE, Novotny PJ, Wolf SL, Linquist B, Kohli S, Smith DR, Loprinzi CL. Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9104] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Reeves B, Dakhil SR, Sloan JA, Kamal A, Wolf SL, Burger KN, LeLindqwister N, Soori GS, Jaslowski AJ, Loprinzi CL. Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Bordeleau L, Jugovic O, Ennis M, Pritchard KI, Warr D, Haq R, Loprinzi CL, Goodwin PJ. A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Moraska AR, Atherton PJ, Szydlo DW, Barton DL, Stella PJ, Rowland KM, Schaefer PL, Krook JE, Bearden J, Loprinzi CL. Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Windschilt HE, Zhao X, Loprinzi CL. Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4025 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant setting. We recently demonstrated the protective effect of CaMg against oxaliplatin-induced sNT as assessed by NCI-CTC (Nikcevich ASCO 2008). It is unclear, though, if CaMg reduced acute and/or chronic, cumulative sNT. Methods: 104 pts with colon cancer undergoing adjuvant therapy with FOLFOX were randomized to IV CaMg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo (PL) in a double-blinded manner. NCI-CTC, an oxaliplatin-specific sNT scale and patient-reported outcome (PRO) questionnaires were used to differentially assess the effect of CaMg on acute (effect on sNT on days 1–4 after oxaliplatin) and chronic sNT (area between curves over whole course of therapy). Results: A total of 102 pts (50 CaMg, 52 PL; 96 mFOLFOX6, 6 FOLFOX4) were available for analysis. Apart from a strong reduction in muscle cramps with CaMg (p=0.002), no difference was found between CaMg and PL in PRO with regard to items reflecting acute sNT (e.g. sensitivity to cold, swallowing of cold liquids, throat discomfort) on days 1–4 after oxaliplatin of any treatment cycle. In contrast, CaMg was able to significantly reduce cumulative sNT in form of numbness in fingers (p=0.02), impaired ability to button shirts (p=0.05), tingling in fingers (p=0.06), and muscle cramps over the course of therapy (p=0.01). Conclusions: In our phase III, placebo-controlled trial, CaMg was able to significantly reduce chronic, cumulative sNT related to oxaliplatin as evaluated by specific PRO questionnaires. No effect was noted on phenomena associated with acute sNT. CaMg can be recommended as neuroprotectant against oxaliplatin-related chronic sNT, oxaliplatin's dose-limiting toxicity. [Table: see text]
Collapse
Affiliation(s)
- A. Grothey
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - D. A. Nikcevich
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - J. A. Sloan
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - J. W. Kugler
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - P. T. Silberstein
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - T. Dentchev
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - D. B. Wender
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - H. E. Windschilt
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - X. Zhao
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - C. L. Loprinzi
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| |
Collapse
|
26
|
Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy B, Rowland KM, Smith DA, Berg A, Stella PJ, Loprinzi CL. The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: A phase III double-blind, placebo controlled study—N05C3 1. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9532] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9532 Background: Chemotherapy induced peripheral neuropathy (CIPN) continues to be a substantial problem for many cancer patients (pts). Pursuant to promising appearing pilot data, the current study evaluated the use of vitamin E for the prevention of CIPN. Methods: A phase III, randomized, double-blind, placebo controlled study was conducted in pts undergoing therapy with neurotoxic chemotherapy, utilizing twice daily dosing of vitamin E (400mg)/placebo. The primary endpoint was the incidence of grade 2+ sensory neuropathy (SN) toxicity (CTCAE v 3.0) in each treatment arm, analyzed by Chi-square testing. Major eligibility criteria included: planned curative intent adjuvant chemotherapy with neurotoxic chemotherapy, ≥ 18 years of age, ECOG PS of ≤2, no existing peripheral neuropathy or coronary artery disease, no prior treatment with neurotoxic chemotherapy, and no concurrent treatment with neuropathic or opioid pain medication. Planned sample size was 100 patients per arm, to provide 80% power to detect a difference in incidence of grade 2+ SN toxicity from 25% in the placebo group to 10% in the vitamin E group. Results: Two-hundred seven pts were enrolled between 12/01/2006 and 12/14/2007. Cytotoxic agents included taxanes (109), cisplatin (8), carboplatin (2), oxaliplatin (50) or combination (20). Eleven pts canceled prior to starting treatment and there were 7 ineligible pts on study. Thus there were 189 evaluable pts included in the current analysis. In this analysis, there was no difference in the incidence of grade 2+ SN between the 2 arms (vitamin E- 34% [95% CI- 25.0–44.8%] placebo- 29% [20.1–39.4%]; P=0.43). There, likewise, were no significant differences between treatment arms for time to onset of neuropathy (P= 0.72), for chemotherapy dose reductions due to neuropathy (P= 0.21) or patient questionnaire reported neuropathy symptoms. The treatment was well tolerated overall. Conclusions: Vitamin E did not appear to reduce the incidence of sensory neuropathy in the studied group of patients receiving neurotoxic chemotherapy but it appeared to be well tolerated. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. A. Kottschade
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - J. A. Sloan
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - M. A. Mazurczak
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - D. B. Johnson
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - B. Murphy
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - K. M. Rowland
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - D. A. Smith
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - A. Berg
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - P. J. Stella
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Sioux Community Cancer Consortium, Sioux Falls, SD; Wichita Community Clinical Oncology Program, Wichita, KS; Metro-MN Community Clinical Oncology Program, St. Louis Park, MN; Carle Cancer Center CCOP, Urbana, IL; Missouri Valley Cancer Consortium, Omaha, NE; Michigan Cancer Research Consortium, Ann Arbor, MI
| |
Collapse
|
27
|
Wolf SL, Qin R, Barton DL, Sloan JA, Liu H, Aaronson NK, Satele DV, Green NB, Mattar BI, Loprinzi CL. Relationship of sensory symptoms and motor function in patients with chemotherapy-induced peripheral neuropathy (CIPN) utilizing the EORTC QLQ CIPN20: NCCTG study N06CA. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9587] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9587 Background: CIPN is characterized by adjectives not covered directly by most common measures of pain and functional limitations. Possible descriptors include numbness, tingling and shooting/burning pain. A prospective neuropathy treatment trial provided data to explore the relationship between self-reported aspects of this symptom. Methods: Baseline EORTC QLQ CIPN20 data and NCI CTCAE V3.0 (CTC)neuropathy grade (I-IV) were provided for all patients on trial. Spearman correlation coefficients and Kappa's coefficients of agreement were calculated between individual items and subscales of the CIPN20 as well as the CTC neuropathy scale. Simple regression models were applied to examine the association between the sensory symptoms and motor function in the fingers/hands (F/H). 200 patients provided 80% power to detect a correlation coefficient of 0.20 with a 5% Type I error. Results: A majority of patients reported “quite a bit” to “very much” numbness (57%) or tingling (62%) in F/H compared to “a little” or “not at all” (numbness (43%), tingling (38%)) by the CIPN20. In contrast, only 13% of the participants had grade III/IV neuropathy determined by the CTC scale. Fewer patients reported the higher two levels of CIPN20-measured shooting/burning pain in F/H (20% “quite a bit” to “very much”). Numbness and tingling were highly correlated (kappa=0.56), while neither were in high agreement with shooting/burning pain (kappa= 0.05 (tingling) and 0.14 (numbness)). The CIPN20 sensory and motor subscales were significantly associated with each other (p<.0001) but were not or only weakly associated with the CTC. Specifically, tingling, numbness, and shooting/burning pain were not associated with the CTC (R=0.16, 0.18 and 0 .11, respectively). Using the CIPN20, all three sensations; numbness, tingling and shooting or burning pain were strongly associated with motor function. Conclusions: The most common moderate to severe CIPN symptoms were numbness and tingling with shooting/burning pain being less common. Shooting/ burning pain appears to be a separate symptom experience from numbness and tingling. The CTC neuropathy grading scale appears to be less sensitive than the CIPN20 in picking up sensory symptoms. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. L. Wolf
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - R. Qin
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - D. L. Barton
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - J. A. Sloan
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - H. Liu
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - N. K. Aaronson
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - D. V. Satele
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - N. B. Green
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - B. I. Mattar
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| |
Collapse
|
28
|
Loprinzi CL, Qin R, Stella PJ, Rowland KM, Graham DL, Erwin N, Dakhil SR, Jurgens DJ, Burger KN. Pregabalin for hot flashes in women: NCCTG trial N07C1. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9513 Background: Hot flashes are a major problem in many women for which better treatment options are needed. Given the known efficacy of gabapentin for decreasing hot flashes, it was decided to evaluate pregabalin, with hopes that it would work better and/or with fewer toxicities. Methods: A three-arm, double-blinded, placebo-controlled randomized trial was developed. Women with bothersome hot flashes (at least 28/week) were randomized to receive either a placebo or target pregabalin oral doses of 75 mg bid or 150 mg bid (starting at 50 mg/d and then increasing the dose at weekly intervals to 50 mg bid, then 75 mg bid, and then, in the higher dose arm, 150 mg bid); patients were treated for 6 weeks. Hot flash numbers and scores (hot flash number times mean severity) were measured using a validated daily hot flash diary. A one-week baseline period preceded initiation of study tablets. The primary endpoint was the average intra-patient difference in hot flash score between baseline and week six, comparing the higher dose pregabalin arm and the placebo arm. With the planned sample size of 55 patients per arm, there was an 80% power and two-sided 5% Type I error rate to detect a difference of 0.54 standard deviations, or 1.08 hot flashes per day, or 2.7 units of hot flash score per day. Results: 207 patients were randomized between 6/20/2008 and 8/21/2008. The study arms were well balanced. Mean/median daily hot flash scores and frequencies for all pts at baseline were 15.7/13.4 and 8.3/7.7, respectively. The table shows the decreases in hot flashes from the baseline to the sixth treatment week. Larger numbers illustrate greater hot flash reductions. Toxicity information, quality of life information, and information regarding the effects of hot flashes on subjective symptoms will be available at the meeting time. Conclusions: Pregabalin reduces hot flashes in women. There appears to be similar effects with both studied doses. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. L. Loprinzi
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - R. Qin
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - P. J. Stella
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - K. M. Rowland
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - D. L. Graham
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - N. Erwin
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - D. J. Jurgens
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - K. N. Burger
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| |
Collapse
|
29
|
Sloan JA, Liu H, Sargent DJ, Satele D, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Loprinzi CL, Buckner JC. A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9599 Background: We have previously identified overall a single-item measure for baseline quality of life (QOL) as a strong prognostic factor for survival (Tan, ASCO 2008), and that fatigue was an important component of patient QOL (Sloan, 2007). To explore whether patient-reported fatigue was supplemental or redundant to the prognostic information of overall QOL, we performed a patient-level pooled analysis of 43 NCCTG and MCCC oncology clinical trials of the effect of baseline fatigue on OS. Methods: 3,915 patients participating in 43 trials provided data at baseline for fatigue on a single-item 0–100 point scale. OS was tested for association with clinically deficient fatigue (CDF, score 0–50, n=1,497) vs not clinically deficient fatigue (nCDF, score 51–100, n=2,418). Cox proportional hazards models adjusted for the effects of overall QOL, performance score, race, disease site, age and gender. Results: Baseline fatigue was a strong predictor of OS for the entire patient cohort (CDF vs. nCDF: 31.5 mos vs >83.9 mos, p<0.0001). The effect sizes were consistent across different disease sites (GI, esophageal, head and neck, prostate, lung, breast and others). After controlling for covariates, including performance status and overall QOL, baseline fatigue remained a strong prognostic factor in multivariate models (CDF vs. nCDF: HR=1.23, p=0.02). Conclusions: Fatigue is a strong prognostic factor for OS independent of overall QOL and PS in a wide variety of oncology patient populations. Single-item measures of overall QOL and fatigue can help to identify vulnerable subpopulations among cancer patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. A. Sloan
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - H. Liu
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - D. J. Sargent
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - D. Satele
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - P. L. Schaefer
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - M. Y. Halyard
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - A. Grothey
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - Y. I. Garces
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - P. D. Brown
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - J. C. Buckner
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| |
Collapse
|
30
|
Abstract
9628 Background: As multiple treatments have been studied for the management of hot flashes in randomized, controlled trials, hot flash placebo responses have been quite variable across trials. Based on observations of trial reports, it was hypothesized that the magnitude of placebo effect might correlate with the number of baseline hot flashes in different studies. The current project examines the effect of the baseline hot flash frequency required for study participation and also the actual number of baseline hot flashes observed as these individually relate to the eventual reductions of hot flash frequency observed in patients receiving placebos. Methods: Data were collected from placebo-controlled, double-blinded, randomized trials, identified by a PubMed search, which reported hot flash frequency at baseline, 4–6 weeks and 12 weeks. Trials were excluded if they had less than 20 participants completing the placebo arm. Data gathered, in each study, included the number of hot flashes required to enroll in the study, the average hot flash number during the baseline period, and the hot flash changes in the placebo arms of each study (percent reduction from the baseline period). A simple statistical analysis was conducted in a descriptive fashion since standard deviation was not available in many trials. Scatter plots and Pearson's correlation coefficients demonstrated the relationships between the placebo hot flash percent reduction from baseline and both the minimum required number of hot flashes at baseline, and the mean number of hot flashes at baseline. Results: 45 trials with 49 placebo arms were included in this analysis. A significant positive correlation was seen between the number of hot flashes required to enroll in a study and the percent reduction of hot flashes from baseline at 4–6 weeks (Rho = 0.481, p = 0.003). There was also a significant positive correlation between the number of hot flashes at baseline and the percent reduction of hot flashes from baseline at 4–6 weeks (Rho = 0.481, p= 0.002) and at 12 weeks (Rho = 0.573, p= 0.003). Conclusions: These data support that higher baseline hot flash enrollment requirements and also higher baseline hot flash frequencies are associated with an increased placebo response. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | - R. Qin
- Mayo Clinic, Rochester, MN
| | | |
Collapse
|
31
|
Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM, Atherton PJ, Marsa GW, Knutson WH, Bearden JD, Kottschade L, Fitch TR. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 2009; 20:542-9. [PMID: 19129205 DOI: 10.1093/annonc/mdn644] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
INTRODUCTION Hot flashes represent a significant problem in men undergoing androgen deprivation therapy. MATERIALS AND METHODS Via a prospective, double-blind, placebo-controlled clinical trial, men with hot flashes, on a stable androgen deprivation therapy program for prostate cancer, received a placebo or gabapentin at target doses of 300, 600, or 900 mg/day. Hot flash frequencies and severities were recorded daily during a baseline week and for 4 weeks while the patients took the study medication. RESULTS In the 214 eligible patients who began the study drug on this trial, comparing the fourth treatment week to the baseline week, mean hot flash scores decreased in the placebo group by 4.1 units and in the three increasing dose gabapentin groups by, 3.2, 4.6, and 7.0 units. Comparing the three combined gabapentin arms to the placebo arm did not result in significant hot flash differences. Wilcoxon rank-sum P values for change in hot flash scores and frequencies after 4 weeks of treatment were 0.10 and 0.02, comparing the highest dose gabapentin arm to the placebo arm, respectively. The gabapentin was well tolerated in this trial. CONCLUSION These results support that gabapentin decreases hot flashes, to a moderate degree, in men with androgen ablation-related vasomotor dysfunction.
Collapse
Affiliation(s)
- C L Loprinzi
- Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Barton DL, Sloan JA, Loprinzi CL, Qin R. Response: Re: Randomized Controlled Trial to Evaluate Transdermal Testosterone in Female Cancer Survivors With Decreased Libido: North Central Cancer Treatment Group Protocol N02C3. J Natl Cancer Inst 2008. [DOI: 10.1093/jnci/djn312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Loprinzi CL, Sloan JA, Stearns V, Diekmann B, Novotny PJ, Kimmick G, Gordon P, Pandya KJ, Guttuso Jr T, Reddy S. Newer antidepressants and gabapentin for hot flashes: An individual subject pooled analysis. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9537] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Liu H, Tan AD, Grothey A, Schaefer PL, Buckner JC, Loprinzi CL, Morton RF, Sloan JA. Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: A pooled analysis of 2,440 patients (pts). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9534] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Bardia A, Novotny PJ, Sloan JA, Barton DL, Steen PD, Watson C, Christensen B, Loprinzi CL. Does efficacy of non-estrogenic therapies for hot flashes among women vary by breast cancer history and tamoxifen use? A pooled analysis. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Barton DL, LaVasseur B, Sloan JA, Stella PJ, Flynn K, Dyar M, Dakhil SR, Atherton PJ, Diekmann B, Loprinzi CL. A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9538] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Mincey BA, Dentchev T, Sloan JA, Hines SL, Perez EA, Johnson DB, Schaefer PL, Liu H, Kahanic SP, Loprinzi CL. N03CC—a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.564] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Nikcevich DA, Grothey A, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Windschitl HE, Loprinzi CL. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4009] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Katipamula R, Hoskin TL, Boughey JC, Degnim AC, Grant CS, Brandt KR, Loprinzi CL, Pruthi S, Goetz MP. Trends in mastectomy rates at the Mayo Clinic Rochester: Effect of surgical year and preoperative MRI. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.509] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner EG, Loprinzi CL, Atherton PJ, Carlson MD, Salim M, Perez EA. N02C1: A phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.525] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Dueck AC, Atherton PJ, Liu H, Hines SL, Loprinzi CL, Perez EA, Tan AD, Burger K, Zhao X, Diekmann B, Sloan JA. Endpoint comparison for osteoporosis assessment in cancer control studies (N02C1 and N03CC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Wolf SL, Loprinzi CL, Maddocks-Christianson K, Rao RD, Dyck PB, Mantyh P, Dyck PJ. Defining the pathophysiology of the paclitaxel-acute pain syndrome. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.19613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
19613 Background: Paclitaxel therapy often results in a unique sub-acute pain syndrome, whose pathophysiology is unknown. While this syndrome is often termed as a ‘myalgia’ or ‘arthralgia’, it has not been demonstrated to be associated with any structural injury of muscles or joints. Identifying the pathophysiology mechanisms that result in the paclitaxel-acute pain syndrome might be a positive step in the development of effective prevention and/or treatment strategies. With the hypothesis that the paclitaxel-acute pain syndrome occurs as a result of nerve injury, an observational study to clarify the clinical characteristics of this syndrome was initiated. Methods: Oncology patients who were treated with at least one dose of paclitaxel and reported developing sub-acute pain were questioned using a detailed structured interview. Various aspects of the pain, including the time of onset, duration, location, severity, and exacerbating factors were evaluated. Data were tabulated descriptively. Results: Eighteen patients were interviewed. The onset of pain typically occurred 1–2 days after therapy and lasted for a median of 4–5 days. Pain was most commonly located in the back, hips, shoulders, thighs, legs and feet, with the most common descriptors used being ‘aching’ or ‘deep pain’. Commonly used adjectives to describe the pain were: ‘radiating’, ‘shooting’, ‘aching’, ‘stabbing’ and ‘pulsating’. Some patients described increased pain with weight bearing or walking. Fifteen of 18 patients specifically denied localization of pain to either joints or muscles. Conclusions: The nature of the pain, i.e. , generalized, deep aching pain, the notation of increased sensitivity with weight bearing (mechanical hyperalgesia) and the lack of localization to joints or muscles, support the hypothesis that the paclitaxel-acute pain syndrome results from a hyperalgesic dysfunction of nociceptive receptors, their fibers, or the spinothalamic system. These clinical conclusions are supported by the recent findings that markers of cellular injury can be identified in peripheral nerve tissues shortly following paclitaxel administration in an animal model (Peters CM, et al., Exp Neurol. 2007 Jan;203(1):42- 54). No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. L. Wolf
- Mayo Clinic, Rochester, MN; University of Minnesota, Minneapolis, MN
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; University of Minnesota, Minneapolis, MN
| | | | - R. D. Rao
- Mayo Clinic, Rochester, MN; University of Minnesota, Minneapolis, MN
| | - P. B. Dyck
- Mayo Clinic, Rochester, MN; University of Minnesota, Minneapolis, MN
| | - P. Mantyh
- Mayo Clinic, Rochester, MN; University of Minnesota, Minneapolis, MN
| | - P. J. Dyck
- Mayo Clinic, Rochester, MN; University of Minnesota, Minneapolis, MN
| |
Collapse
|
43
|
Barton DL, Soori GS, Bauer B, Sloan J, Johnson PA, Figueras C, Duane S, Dakhil S, Liu H, Loprinzi CL. A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9001 Background: Fatigue is one of the most common symptoms in people diagnosed with cancer. Ginseng is a popular herb for treatment of this. It has been termed an “adaptogen”, felt to be able to restore balance to the body; its potential anti-fatigue efficacy is supported by animal data. The purpose of this pilot trial was to evaluate three doses of American Ginseng versus placebo for cancer-related fatigue. Methods: Patients with a life expectancy = 6 months and a history of cancer-related fatigue who had been experiencing fatigue = 1 month were eligible. Exclusion criteria included prior use of ginseng, chronic systemic steroids and brain malignancies. Other etiologies for fatigue, such as pain, were also excluded. Participants were randomized to receive, in a double blind manner, placebo, 750 mg/d, 1,000 mg/d or 2,000 mg/d of American Ginseng in BID dosing for 8 weeks. Endpoints included The Brief Fatigue Inventory (BFI), the Vitality Subscale of the SF-36 and several numeric analogue questions of perceived benefit; endpoints were measured at baseline, 4 weeks and 8 weeks. Area under the curve (AUC) and change from baseline were calculated. Results: Two hundred eighty two patients (69–72 per arm) were enrolled from 10/21/2005 to 07/05/2006. Available 8-week data are provided in the table below; higher numbers are better. There were no statistically significant differences in any grade of toxicity between active and placebo arms, and an equivalent number of patients discontinued the study due to adverse events in each arm. Conclusion: This randomized pilot trial provided data to suggest that American Ginseng doses of 1000–2000 mg/d may be effective for alleviating cancer related fatigue. Therefore, further study of American Ginseng in cancer survivors appears warranted. No significant financial relationships to disclose. [Table: see text]
Collapse
Affiliation(s)
- D. L. Barton
- Mayo Clinic College of Medicine, Rochester, MN; Missouri Valley Cancer Consortium, Omaha, NE; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; Michigan Cancer Research Consortium, Ann Arbor, MI; Metro-Minnesota CCOP, St. Louis Park, MN; Wichita CCOP, Wichita, KS
| | - G. S. Soori
- Mayo Clinic College of Medicine, Rochester, MN; Missouri Valley Cancer Consortium, Omaha, NE; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; Michigan Cancer Research Consortium, Ann Arbor, MI; Metro-Minnesota CCOP, St. Louis Park, MN; Wichita CCOP, Wichita, KS
| | - B. Bauer
- Mayo Clinic College of Medicine, Rochester, MN; Missouri Valley Cancer Consortium, Omaha, NE; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; Michigan Cancer Research Consortium, Ann Arbor, MI; Metro-Minnesota CCOP, St. Louis Park, MN; Wichita CCOP, Wichita, KS
| | - J. Sloan
- Mayo Clinic College of Medicine, Rochester, MN; Missouri Valley Cancer Consortium, Omaha, NE; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; Michigan Cancer Research Consortium, Ann Arbor, MI; Metro-Minnesota CCOP, St. Louis Park, MN; Wichita CCOP, Wichita, KS
| | - P. A. Johnson
- Mayo Clinic College of Medicine, Rochester, MN; Missouri Valley Cancer Consortium, Omaha, NE; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; Michigan Cancer Research Consortium, Ann Arbor, MI; Metro-Minnesota CCOP, St. Louis Park, MN; Wichita CCOP, Wichita, KS
| | - C. Figueras
- Mayo Clinic College of Medicine, Rochester, MN; Missouri Valley Cancer Consortium, Omaha, NE; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; Michigan Cancer Research Consortium, Ann Arbor, MI; Metro-Minnesota CCOP, St. Louis Park, MN; Wichita CCOP, Wichita, KS
| | - S. Duane
- Mayo Clinic College of Medicine, Rochester, MN; Missouri Valley Cancer Consortium, Omaha, NE; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; Michigan Cancer Research Consortium, Ann Arbor, MI; Metro-Minnesota CCOP, St. Louis Park, MN; Wichita CCOP, Wichita, KS
| | - S. Dakhil
- Mayo Clinic College of Medicine, Rochester, MN; Missouri Valley Cancer Consortium, Omaha, NE; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; Michigan Cancer Research Consortium, Ann Arbor, MI; Metro-Minnesota CCOP, St. Louis Park, MN; Wichita CCOP, Wichita, KS
| | - H. Liu
- Mayo Clinic College of Medicine, Rochester, MN; Missouri Valley Cancer Consortium, Omaha, NE; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; Michigan Cancer Research Consortium, Ann Arbor, MI; Metro-Minnesota CCOP, St. Louis Park, MN; Wichita CCOP, Wichita, KS
| | - C. L. Loprinzi
- Mayo Clinic College of Medicine, Rochester, MN; Missouri Valley Cancer Consortium, Omaha, NE; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; Michigan Cancer Research Consortium, Ann Arbor, MI; Metro-Minnesota CCOP, St. Louis Park, MN; Wichita CCOP, Wichita, KS
| |
Collapse
|
44
|
Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM, Perrin N. Prognostic significance of patient-physician disagreement about performance status in patients with advanced cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9021 Background: Physician-reported performance status (PS) is an important prognostic factor in advanced malignancies and is a commonly used stratification variable in cancer clinical trials. However, the extent, predictors, and prognostic importance of disagreement in PS assessment between physicians and patients have not been examined. Methods: Using NCCTG clinical trials from 1987–1990 (J Clin Oncol 19(15):3539–3546, 2001), we analyzed the difference and agreement of PS (ECOG and Karnofsky [KPS]) and nutritional status assessments reported by physicians and patients individually. The degree of disagreement was analyzed using paired t-test. Overall mortality was estimated by Kaplan-Meier method. The effect of disagreement on overall survival was analyzed by Cox regression. Independent predictors of disagreement were identified by logistic regression. Results: 1,636 patients with advanced lung and colorectal cancer had a median survival of 9.8 months (95% CI, 9.4 to 10.4). Percent agreement between patients and physicians about KPS, ECOG PS, and appetite/nutritional status was 32.9%, 43.4% and 42.0% respectively. Physicians were more likely to rate patients better than individual patients were to rate themselves: ECOG (Mean 0.91 vs 1.30, p<.0001), KPS (Mean 83.3 vs. 81.7, p<0.0001), appetite/nutritional status (Mean 1.6 vs. 2.1, p<0.0001). Inability to work, depression and less than a high school education were independently associated with disagreement. An increased risk of death was observed for patient and physician disagreement on KPS (HR=1.15, 95% CI, 1.03 to 1.27 p=0.01) and appetite/nutritional status (HR=1.39, 95% CI, 1.26 to 1.54 p<0.0001). Conclusions: Patients and physicians frequently disagree about patient PS, with physicians tending to rate patients higher than patients do themselves. Baseline patient demographic factors that independently predict disagreement have been identified. Disagreement confers an increased risk of death in the setting of advanced malignancies. These findings illustrate limitations of physician-only assessed PS. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. D. Schnadig
- Oregon Health & Science University, Portland, OR; Mayo Clinic, Rochester, MN
| | - E. K. Fromme
- Oregon Health & Science University, Portland, OR; Mayo Clinic, Rochester, MN
| | - C. L. Loprinzi
- Oregon Health & Science University, Portland, OR; Mayo Clinic, Rochester, MN
| | - J. A. Sloan
- Oregon Health & Science University, Portland, OR; Mayo Clinic, Rochester, MN
| | - M. Mori
- Oregon Health & Science University, Portland, OR; Mayo Clinic, Rochester, MN
| | - H. Li
- Oregon Health & Science University, Portland, OR; Mayo Clinic, Rochester, MN
| | - T. M. Beer
- Oregon Health & Science University, Portland, OR; Mayo Clinic, Rochester, MN
| | - N. Perrin
- Oregon Health & Science University, Portland, OR; Mayo Clinic, Rochester, MN
| |
Collapse
|
45
|
Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Perez EA, Goetz MP. How well do standard prognostic criteria predict oncotype DX (ODX) scores? J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.576] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
576 Background: In node-negative, ER + breast cancer, gene expression profiling can identify level of risk and, in the case of ODX, may also identify pts with a higher chance of benefiting from adjuvant chemotherapy. Because the gene profile in ODX includes an assessment of ER, HER2, and proliferation, we hypothesized that clinicians using standardized criteria could discriminate risk (high versus low/intermediate) as specified by ODX. Methods: We identified Mayo Clinic patients with node-negative, ER + breast cancer, for whom ODX scores were available. Tumor slides were reviewed by an expert breast pathologist to confirm tumor size, histology, and tumor grade. Both ER and PR were quantitated; HER-2 was determined by IHC (FISH, if 2+). These clinical cases were presented to six academic oncologists, blinded to the ODX score, to predict ODX risk (low, intermediate, or high) and give their recommendation for chemotherapy (CTX) (yes/no). Afterwards, they were presented with the same cases with the actual ODX score, to give recommendations regarding CTX. Results: ODX scores in tumors from 31 patients were low in 18 pts, intermediate in 10 pts, and high in 3 pts. Concordance between predicted and actual ODX scores being low/intermediate vs high exceeded 87% for each oncologist. The most frequent discrepancies were actual low scores predicted as intermediate (31/80 discordant) and actual intermediate scores predicted as low (29/80 discordant). Overall agreement of predicted scores (high vs low/intermediate) among the oncologists was substantial (kappa=0.75, p<0.0001). CTX recommendations following provision of the ODX scores changed on average 18.2% (range 12.9%-25.8%) of the time, with slightly fewer changing for, versus against, a CTX recommendation. Conclusions: Our findings suggest that the proper evaluation and interpretation of traditional prognostic criteria will identify most node negative, ER + patients at high risk of recurrence (as predicted by ODX) but poorly discriminate low versus intermediate risk. The provision of ODX data changed the recommendation for CTX in approximately 20% of cases. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. H. Kamal
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| | - C. Reynolds
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| | - A. C. Dueck
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| | - X. J. Geiger
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| | - J. N. Ingle
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| | - R. W. Carlson
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| | - T. J. Hobday
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| | - E. P. Winer
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| | - E. A. Perez
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| | - M. P. Goetz
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Stanford Comprehensive Cancer Center, Palo Alto, CA; Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
46
|
Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Dakhil SR, Loprinzi CL. Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.lba9006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA9006 Purpose: Many patients who receive EGFR inhibitors develop an acneiform rash, and anecdotal reports suggest tetracycline is effective in treating it. To our knowledge, however, no rigorous trials have ever been published to substantiate this approach. This double- blinded, placebo-controlled trial was conducted to assess the role of tetracycline in preventing EGFR inhibitor-induced rash and/or reducing its severity. Methods: 61 patients were randomly assigned to tetracycline 500 mg orally twice a day×4 weeks versus an identical, similarly prescribed placebo. Eligibility criteria required all patients to have begun an EGFR inhibitor </= 7 days prior with no rash at study entry. Patients were to be followed for 8 weeks. Physician assessments of rash incidence, severity, and adverse events, occurred at 4 and 8 weeks. Patients completed a weekly rash diary, quality of life questionnaire (SKINDEX-16), and EGFR inhibitor compliance questionnaire. Thirty patients per group provides 90% power to detect a difference in rash incidence (the primary endpoint) of 40% between groups and of rejecting the null hypothesis of equal proportions with a type I error of 5% (2-sided). Results: Treatment arms were balanced on baseline characteristics, drop out rates, and rates of discontinuation of the EGFR inhibitor. Rash incidence was comparable across arms. Physicians reported that 16 tetracycline-treated patients (70%) and 22 placebo-exposed patients (76%) developed a rash (p=0.61). However, tetracycline appears to have lessened rash severity. By week 4, physician-reported grade 2 rash occurred in 17% of tetracycline-treated patients (n=4) and 55% of placebo- exposed patients (n=16); (p=0.04). Tetracycline-treated patients reported better scores on certain quality of life parameters (SKINDEX-16), such as skin burning or stinging, skin irritation, and being bothered by a persistence/recurrence of a skin condition. Adverse events were comparable across arms. Conclusion: Tetracycline did not prevent EGFR inhibitor-induced rashes. However, diminished rash severity and improved quality of life suggest this antibiotic merits further study. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Jatoi
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - K. Rowland
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - J. A. Sloan
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - H. M. Gross
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - P. A. Fishkin
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - S. P. Kahanic
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - P. J. Novotny
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - P. L. Schaefer
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - S. R. Dakhil
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - C. L. Loprinzi
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| |
Collapse
|
47
|
Loprinzi CL, Khoyratty BS, Dueck A, Barton DL, Jafar S, Rowland KM, Atherton PJ, Marsa GW, Krook J, Kottschade L. Gabapentin for hot flashes in men: NCCTG trial N00CB. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9005 Background: Hot flashes can be a major problem in men with prostate cancer; effective non-hormonal options are needed. Methods: A four-arm, double-blinded, placebo-controlled randomized trial was developed to evaluate gabapentin for hot flashes. Men with bothersome hot flashes (at least 14/week) related to androgen deprivation therapy were randomized to receive either a placebo or gabapentin doses of 300 mg qd, 300 mg bid or 300 mg tid; men were treated for 4 weeks. Hot flashes numbers and scores (hot flash number times mean severity) were measured using a validated daily hot flashes diary. A one-week baseline period preceded initiation of study tablets. The primary endpoint was the average intrapatient difference in hot flash score between baseline and treatment termination. With the planned sample size of 50 evaluable patients per arm, the study provided 80% power to detect a difference in change from baseline at 4 weeks between each gabapentin arm and the placebo arm of 1.3 hot flashes per day or 3.3 points in hot flash score. Results: 223 patients were randomized between 12/21/2001 and 11/10/2006. The study arms were well balanced. The following table illustrates the percentage of baseline hot flash scores and frequencies during the fourth treatment week, compared to the baseline week for 179 eligible patients, utilizing the data available at time of this abstract preparation. Patients receiving 900 mg/d dose of gabapentin also reported significantly less hot flash distress and more hot flash control satisfaction than did the placebo group. The gabapentin was remarkably well tolerated, without any statistically significantly worse patient-reported side effects on the gabapentin arms. Conclusion: Gabapentin at the 900 mg/d dose can reduce hot flashes, in men receiving androgen deprivation therapy for prostate cancer. No significant financial relationships to disclose. [Table: see text]
Collapse
Affiliation(s)
- C. L. Loprinzi
- Mayo Clinic College of Medicine, Rochester, MN; Metro-Minnesota Community Clinical Oncology, St. Louis Park, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Flower Hospital, Sylvania, OH; Duluth Clinic Ltd, Duluth, MN
| | - B. S. Khoyratty
- Mayo Clinic College of Medicine, Rochester, MN; Metro-Minnesota Community Clinical Oncology, St. Louis Park, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Flower Hospital, Sylvania, OH; Duluth Clinic Ltd, Duluth, MN
| | - A. Dueck
- Mayo Clinic College of Medicine, Rochester, MN; Metro-Minnesota Community Clinical Oncology, St. Louis Park, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Flower Hospital, Sylvania, OH; Duluth Clinic Ltd, Duluth, MN
| | - D. L. Barton
- Mayo Clinic College of Medicine, Rochester, MN; Metro-Minnesota Community Clinical Oncology, St. Louis Park, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Flower Hospital, Sylvania, OH; Duluth Clinic Ltd, Duluth, MN
| | - S. Jafar
- Mayo Clinic College of Medicine, Rochester, MN; Metro-Minnesota Community Clinical Oncology, St. Louis Park, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Flower Hospital, Sylvania, OH; Duluth Clinic Ltd, Duluth, MN
| | - K. M. Rowland
- Mayo Clinic College of Medicine, Rochester, MN; Metro-Minnesota Community Clinical Oncology, St. Louis Park, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Flower Hospital, Sylvania, OH; Duluth Clinic Ltd, Duluth, MN
| | - P. J. Atherton
- Mayo Clinic College of Medicine, Rochester, MN; Metro-Minnesota Community Clinical Oncology, St. Louis Park, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Flower Hospital, Sylvania, OH; Duluth Clinic Ltd, Duluth, MN
| | - G. W. Marsa
- Mayo Clinic College of Medicine, Rochester, MN; Metro-Minnesota Community Clinical Oncology, St. Louis Park, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Flower Hospital, Sylvania, OH; Duluth Clinic Ltd, Duluth, MN
| | - J. Krook
- Mayo Clinic College of Medicine, Rochester, MN; Metro-Minnesota Community Clinical Oncology, St. Louis Park, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Flower Hospital, Sylvania, OH; Duluth Clinic Ltd, Duluth, MN
| | - L. Kottschade
- Mayo Clinic College of Medicine, Rochester, MN; Metro-Minnesota Community Clinical Oncology, St. Louis Park, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Flower Hospital, Sylvania, OH; Duluth Clinic Ltd, Duluth, MN
| |
Collapse
|
48
|
Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Carlson MD, Duane SF, Corso SW. Phase III randomized trial to evaluate the use of gabapentin alone vs with continuing an antidepressant in women failing an antidepressant for the treatment of hot flashes: North Central Cancer Treatment Group Study N00C3. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
526 Background: Antidepressants do not adequately alleviate all HFs. Based on placebo-controlled data demonstrating that GABA is an alternative therapy for HFs, this trial was initiated to test whether the combination of an antidepressant and GABA was better than GABA alone in PTS with inadequate HF control on an antidepressant alone. Methods: Eligible PTS on antidepressants with bothersome HFs were randomized to two groups. PTS kept a daily HF diary during a baseline wk (while continuing their antidepressant). Following the baseline wk, all PTS were given GABA 300 mg at hs for 3 days, then BID for 3 days, and then TID for 22 days. One group continued their antidepressant while the other group was weaned off it over several days. PTS continued a daily HF diary during this 4-wk period. Efficacy was measured using the mean daily HF number and score; the latter measured by assigning points (1–4, for mild to very severe) to each HF and then adding the points for a given time. The study design provided 80% power to detect a difference in the changes from baseline at 4 wks between the two groups of 1.2 HFs/day, or 3 points/day in HF scores. Results: 115 PTS were randomized and given GABA. PTS continuing their antidepressant reported a 48% mean reduction in HF score after 4 wks, vs 49% for PTS stopping it (p=0.97). Mean HF numbers were reduced 50% and 47%, respectively (p=0.54). 16 other symptoms and quality of life items were measured by PT-completed weekly questionnaires, with the only suggestive changes from baseline between the two arms being more mood troubles after 2 wks of treatment (p=0.06) and more nervousness after 4 wks of treatment (p=0.01) in PTS stopping their antidepressant. Also, a mild temporary increase in dizziness after 1 wk of treatment was observed in the same group (p=0.08) suggestive of an antidepressant withdrawal reaction. Conclusion: This trial failed to provide any evidence that the combination of GABA and an antidepressant decreased HFs any more than did GABA alone in PTS who had inadequate HF control with an antidepressant alone. The 50% reduction in HFs in both arms is commensurate with the efficacy of GABA delineated in other published reports. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. L. Loprinzi
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association CCOP, Peoria, IL; Sioux Community Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Spartanburg Regional Medical Center, Spartanburg, SC
| | - J. W. Kugler
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association CCOP, Peoria, IL; Sioux Community Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Spartanburg Regional Medical Center, Spartanburg, SC
| | - D. L. Barton
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association CCOP, Peoria, IL; Sioux Community Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Spartanburg Regional Medical Center, Spartanburg, SC
| | - A. C. Dueck
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association CCOP, Peoria, IL; Sioux Community Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Spartanburg Regional Medical Center, Spartanburg, SC
| | - L. K. Tschetter
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association CCOP, Peoria, IL; Sioux Community Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Spartanburg Regional Medical Center, Spartanburg, SC
| | - R. A. Nelimark
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association CCOP, Peoria, IL; Sioux Community Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Spartanburg Regional Medical Center, Spartanburg, SC
| | - E. P. Balcueva
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association CCOP, Peoria, IL; Sioux Community Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Spartanburg Regional Medical Center, Spartanburg, SC
| | - M. D. Carlson
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association CCOP, Peoria, IL; Sioux Community Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Spartanburg Regional Medical Center, Spartanburg, SC
| | - S. F. Duane
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association CCOP, Peoria, IL; Sioux Community Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Spartanburg Regional Medical Center, Spartanburg, SC
| | - S. W. Corso
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association CCOP, Peoria, IL; Sioux Community Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Spartanburg Regional Medical Center, Spartanburg, SC
| |
Collapse
|
49
|
Jatoi A, Dakhil SR, Kugler JW, Rowland KM, Keit J, Verdirame JD, Novotny PJ, Sloan JA, Nguyen PL, Loprinzi CL. A placebo-controlled trial of etanercept, a tumor necrosis factor (TNF) inhibitor, in patients with the cancer anorexia/weight loss syndrome. North Central Cancer Treatment Group (NCCTG) trial N00C1. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8534 Purpose: Tumor necrosis factor (TNF) is a putative mediator of the cancer anorexia/weight loss syndrome. This study was designed to determine if etanercept (a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton TNF receptor linked to the Fc portion of human IgG1) could palliate this syndrome. Methods: 63 evaluable patients were randomly assigned to etanercept 25 mg SQ twice/week versus a comparably-administered placebo, both of which were to be given for at least 12 weeks. All patients had an incurable malignancy, acknowledged loss of weight and/or appetite as a concern, and reported weight loss of > 5 pounds over 2 months and/or a daily intake of < 20 calories/kg body weight. The above sample size provided 81% power to detect a 24% difference in the percentage of patients who gained >/= 10% of baseline weight. Results: At baseline, groups were comparable on age, gender, tumor type, and degree of weight loss. Over time, weight gain was minimal in both groups; no patient gained >/= 10% baseline weight. Appetite questionnaires (the NCCTG Anorexia/Cachexia Questionnaire and FACT-AN) revealed negligible improvements in both groups. Median survival was comparable: 175 days versus 148 in etanercept-treated and placebo-exposed patients, respectively (p=0.82). Finally, preliminary data on adverse events showed that etanercept-treated patients had higher rates of neurotoxicity (29% versus 0%) but lower rates of anemia (0% versus 19%) and thrombocytopenia (0% versus 14%). Infection rates were negligible in both groups. Clinical correlative data on TNF genotyping will be available at the time of the meeting. Conclusion: This TNF inhibitor does not appear to palliate the cancer anorexia/weight loss syndrome. The study was supported by CA37404, the American Institute for Cancer Research, and Amgen. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Jatoi
- Mayo Clinic College of Medicine, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Oncology Hematology Associates, Peoria, IL; Carle Cancer Center, Urbana, IL; Alegent Health Immanuel Medical Center, Omaha, NE
| | - S. R. Dakhil
- Mayo Clinic College of Medicine, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Oncology Hematology Associates, Peoria, IL; Carle Cancer Center, Urbana, IL; Alegent Health Immanuel Medical Center, Omaha, NE
| | - J. W. Kugler
- Mayo Clinic College of Medicine, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Oncology Hematology Associates, Peoria, IL; Carle Cancer Center, Urbana, IL; Alegent Health Immanuel Medical Center, Omaha, NE
| | - K. M. Rowland
- Mayo Clinic College of Medicine, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Oncology Hematology Associates, Peoria, IL; Carle Cancer Center, Urbana, IL; Alegent Health Immanuel Medical Center, Omaha, NE
| | - J. Keit
- Mayo Clinic College of Medicine, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Oncology Hematology Associates, Peoria, IL; Carle Cancer Center, Urbana, IL; Alegent Health Immanuel Medical Center, Omaha, NE
| | - J. D. Verdirame
- Mayo Clinic College of Medicine, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Oncology Hematology Associates, Peoria, IL; Carle Cancer Center, Urbana, IL; Alegent Health Immanuel Medical Center, Omaha, NE
| | - P. J. Novotny
- Mayo Clinic College of Medicine, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Oncology Hematology Associates, Peoria, IL; Carle Cancer Center, Urbana, IL; Alegent Health Immanuel Medical Center, Omaha, NE
| | - J. A. Sloan
- Mayo Clinic College of Medicine, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Oncology Hematology Associates, Peoria, IL; Carle Cancer Center, Urbana, IL; Alegent Health Immanuel Medical Center, Omaha, NE
| | - P. L. Nguyen
- Mayo Clinic College of Medicine, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Oncology Hematology Associates, Peoria, IL; Carle Cancer Center, Urbana, IL; Alegent Health Immanuel Medical Center, Omaha, NE
| | - C. L. Loprinzi
- Mayo Clinic College of Medicine, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Oncology Hematology Associates, Peoria, IL; Carle Cancer Center, Urbana, IL; Alegent Health Immanuel Medical Center, Omaha, NE
| |
Collapse
|
50
|
Renno SI, Rao RD, Sloan J, Wong G, Johnson D, Howard GM, Novotny P, Patrick FJ, Loprinzi CL. The efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase III randomized, double blind, placebo-controlled NCCTG trial, N01C3. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8530] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8530 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose limiting complication of chemotherapy. Lamotrigine (an anti-convulsant drug) appears to have some benefit when used to treat pain from neuropathy due to various etiologies. Based on these data, we conducted a phase III randomized placebo controlled study to determine the efficacy of lamotrigine in treating symptoms from CIPN. Methods: Patients with CIPN for 1 month or more were randomly assigned to lamotrigine (target dose 300 mg/day, increased by 50 mg/2 weeks) or placebo for 10 weeks. The co-primary endpoints were differences in average CIPN symptoms assessed by pro-rated area under the curve (AUC) of a numerical pain rating scale (NRS) and the Eastern Cooperative Oncology Group sensory neuropathy (ESN) scale. Accrual of 60 patients per group provided t-tests with 80% power to detect a difference of 0.57 standard deviation for each co-primary endpoint (moderate effect size) with a type I error of 0.025. Results: 131patients were enrolled, with complete data available for analysis in 93 (72%). Analyses were limited to this cohort but will be updated. Chemotherapy drugs considered to be causative of the CIPN were vinca alkaloids (30%), taxanes (25%), platinum-agents (7%), combinations (34%), and others (3%). Patients were equally matched with regards to baseline characteristics. Patients who enrolled had severe symptoms, with a baseline median ESN at enrollment of 3 (out of 3) in both groups. Toxicities were similar in both groups, however, more patients discontinued lamotrigine due to toxicities/refusals than those on placebo (32% vs 13% resp; p=0.04) and were therefore less likely to complete the 10 weeks therapy (60% vs. 78% resp, p=0.08). Average AUC of NRS score for patients on lamotrigine and placebo was 30.5 and 33.7 resp (p=0.48). The corresponding average AUC of the ESN scores were 12.4 and 14.5 (p=0.23). The proportions of patients with a 10 point (of 100) improvement in worst pain score (39% vs 36%) and a 1 point change in ESN (25% vs 27%) were similar between the lamotrigine and placebo arms, resp. Conclusions: These results suggest that lamotrigine is not effective for managing pain and symptoms due to CIPN. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. I. Renno
- Hematology Oncology Consult PC, Omaha, NE; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN
| | - R. D. Rao
- Hematology Oncology Consult PC, Omaha, NE; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN
| | - J. Sloan
- Hematology Oncology Consult PC, Omaha, NE; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN
| | - G. Wong
- Hematology Oncology Consult PC, Omaha, NE; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN
| | - D. Johnson
- Hematology Oncology Consult PC, Omaha, NE; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN
| | - G. M. Howard
- Hematology Oncology Consult PC, Omaha, NE; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN
| | - P. Novotny
- Hematology Oncology Consult PC, Omaha, NE; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN
| | - F. J. Patrick
- Hematology Oncology Consult PC, Omaha, NE; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN
| | - C. L. Loprinzi
- Hematology Oncology Consult PC, Omaha, NE; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Hematology and Oncology of Dayton, Inc, Dayton, OH; Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN
| |
Collapse
|